Baxter International Inc. 2002 Annual Report (10-K) Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2002. Baxter International Inc. is a global medical products and services company operating in three primary segments: Medication Delivery (IV solutions and specialty products), BioScience (biopharmaceuticals and blood therapies), and Renal (dialysis products and services). The company manufactures in 29 countries and sells in over 100 countries. As of December 31, 2002, the company employed approximately 54,600 people.
Key Financial Metrics
Specific consolidated revenue, net income, and cash flow figures for 2002 are incorporated by reference to the Annual Report to Stockholders and are not explicitly stated in the provided text. However, the following specific financial data points are disclosed:
- Research & Development (R&D): $501 million in 2002 (compared to $426 million in 2001 and $378 million in 2000).
- Capital Expenditures: $734 million in 2002 (compared to $641 million in 2001 and $524 million in 2000).
- Equipment Leased to Customers: $114 million in additions for 2002.
- Debt Ratings (as of March 1, 2003): A3 (Moody's), A (S&P), and A (Fitch).
- Market Capitalization: Approximately $26.7 billion (based on non-affiliate voting equity as of June 28, 2002).
- Outstanding Shares: 596,996,864 shares of common stock as of February 28, 2003.
- Valuation Reserves (Year-end 2002): Litigation reserves totaled $232 million; Inventory reserves totaled $118 million; Allowance for doubtful accounts totaled $62 million.
Material Changes and Operational Highlights
The company experienced significant strategic and operational shifts in 2002:
- Acquisitions: Acquired ESI Lederle (injectable drugs), AUTROS Healthcare Solutions (medication safety IT), and Fusion Medical Technologies (hemostasis). Announced an agreement to acquire Alpha Therapeutic Corporation's Aralast product.
- Divestitures: Announced plans to divest most of its renal services businesses, including U.S.-based RMS Disease Management and RMS Lifeline, and most international Renal Therapy Services dialysis centers.
- Product Launches: Introduced bar-code technology for infusion pumps, Mesnex Tablets, and the Accura system for continuous renal replacement therapy. Received FDA approval for Extraneal PD solution.
- Customer Concentration: Sales to Premier Purchasing Partners L.P. represented 8.9% of consolidated net sales in 2002, down from 10.1% in 2001.
Outlook, Risks, and Contingencies
Management's outlook focuses on geographic expansion, cost reduction, and new product launches. However, the filing highlights significant risks and contingencies:
- Legal Proceedings:
- Mammary Implants: Defendant in 129 lawsuits involving silicone implants from the former Heyer-Schulte division. Insurance coverage is estimated to exceed $900 million.
- Plasma-Based Therapies: Facing lawsuits regarding HIV transmission from factor concentrates (1978-1985) and Hepatitis C from Gammagard IVIG. Settlements are ongoing in the U.S. and Japan.
- Althane Dialyzers: Defendant in six civil lawsuits regarding patient deaths; a criminal investigation is pending in Spain.
- Securities Litigation: Subject to consolidated class actions alleging misleading statements regarding stock price inflation.
- Drug Pricing: Facing multiple lawsuits and government investigations regarding artificially inflated prices for Medicare/Medicaid drugs.
- Market Risks: Currency fluctuations, particularly a strengthening U.S. dollar, could negatively impact international sales growth. The company also faces intense price competition and consolidation in the healthcare customer base.
- Regulatory Risks: Operations are subject to strict regulation by the FDA and international agencies regarding product safety, manufacturing, and labeling.
Investor Verification Checklist
- Verify the full consolidated revenue and net income figures in the referenced Annual Report to Stockholders, as they are not explicitly listed in this 10-K text.
- Review the status of the planned divestiture of the Renal services business to understand the impact on future revenue streams.
- Monitor the resolution of the Althane dialyzer litigation and the Spanish criminal investigation, as these could result in material charges.
- Assess the impact of the 8.9% sales concentration with Premier Purchasing Partners and the renewal status of those contracts.
- Confirm the sufficiency of the $232 million litigation reserve against potential future settlements for mammary implant and plasma therapy claims.